LSTA — Lisata Therapeutics Income Statement
0.000.00%
- $29.49m
- -$14.11m
- 26
- 43
- 63
- 40
Annual income statement for Lisata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 52 W | 52 W | 52 W | 52 W | 52 W |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 20.1 | 19.1 | 29.1 | 57.6 | 25.7 |
Operating Profit | -20.1 | -19.1 | -29.1 | -57.6 | -25.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.4 | -19 | -29 | -56.7 | -23.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.4 | -8.14 | -27.5 | -54.2 | -20.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -19.4 | -8.15 | -27.5 | -54.2 | -20.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.4 | -8.15 | -27.5 | -54.2 | -20.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -28.1 | -7.92 | -7.45 | -10.5 | -2.58 |